SLC5A2 and atrial fibrillation: Beyond interdrug comparisons, adverse cardiovascular outcomes in our cohort were more closely associated with advanced age, the presence of atrial fibrillation (AF), and reduced ejection fraction—rather than the type of SGLT2 inhibitor used.